Core Viewpoint - Zhongjin Irradiation (300962.SZ) has announced a plan to issue A-shares to specific investors, including China National Gold Group, with a total fundraising amount not exceeding RMB 800 million [1] Group 1: Fundraising Details - The fundraising will involve no more than 35 specific investors, in compliance with the regulations set by the China Securities Regulatory Commission [1] - China National Gold Group, the controlling shareholder, will subscribe to the shares for RMB 100 million [1] Group 2: Use of Proceeds - The net proceeds from the fundraising, after deducting related issuance costs, are intended for several projects, including: - Changsha Sterilization Technology Service Center Project - Hefei Comprehensive Sterilization Technology Center Project - Phase II of the annual sterilization medical device project in Jiaxing, with a capacity of 300,000 cubic meters - Cobalt source procurement project - Supplementing working capital [1]

Group 1: Company Overview - The company is a member of the International Irradiation Association and serves as the vice-chairman unit of the China Isotope and Radiation Association, being one of the earliest enterprises to industrialize irradiation technology in China [2][3] - It has developed into one of the most specialized irradiation sterilization companies in China, with the highest cobalt source activity and the most comprehensive network layout [3] Group 2: Equipment and Technology - The company owns gamma and electron accelerator irradiation devices in cities including Shenzhen, Shanghai, Tianjin, Qingdao, Wuhan, Chengdu, Chongqing, Jiaxing, and Changsha (under construction) [2] - Gamma irradiation is noted for its strong penetration, wide application, and low carbon environmental benefits, while electron accelerators are recognized for their high efficiency and controllable radiation [2] Group 3: Production Capacity and Expansion - The company has sufficient cobalt sources to meet continuous operational demands and can expand production capacity based on market needs [2][3] - Future capacity expansion may involve supplementing cobalt sources in existing facilities or adding new devices at current and new sites [2] Group 4: Financial Performance - The company's gross margin is influenced by production scale, product structure, irradiation pricing, and production costs, with rising cobalt procurement prices impacting costs [3] - The company plans to enhance gross margin through diversified sourcing, optimizing product structure, and strengthening cost control [3] Group 5: Customer Base and Market Position - The top five customers account for approximately 14.81% of total annual sales, with each contributing around 3%, indicating low customer concentration [3] - The company maintains long-term strategic partnerships across various industries, including healthcare, food, pharmaceuticals, daily necessities, and packaging materials [3] Group 6: Future Financing Plans - The company has a low debt-to-asset ratio and plans to use a mix of equity and debt financing to support its development needs [3]